Navigation Links
Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
Date:9/3/2007

Report of Positive Results with Innovative Pro-Healing Stent is Featured at

ESC Congress 2007

VIENNA, Austria, Sept. 3 /PRNewswire/ -- OrbusNeich today announced that post-marketing data from patient subsets of a global registry support the use of the company's Genous(TM) Bio-engineered R stent(TM) as an alternative to drug-eluting stents.

Presented today by Robbert de Winter, M.D., Ph.D., at the European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from OrbusNeich's e-HEALING registry show:

* For 296 diabetic patients at six months, the target lesion

revascularization (TLR) rate was 2%, which is much lower than was

anticipated

* A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]

six months

* For 923 patients with statin use, the major adverse cardiac events

(MACE) rate at six months was 5.7%, while 116 patients without statin

use experienced a MACE rate of 6.9% over the same period

"This real-world data strengthen our belief that Genous is a very promising alternative to drug-eluting stents," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "Genous appears to have the same efficacy as drug-eluting stents but a better safety profile with only minimal dual-antiplatelet therapy requirements. This is an important finding in that physicians are becoming reluctant to burden their patients with the cost and compliance issues associated with drug-eluting stents and their extensive dual-antiplatelet therapy requirements."

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry of patients treated with the Genous Bio- engineered R stent in accordance with the instructions for use. The protocol recommends that patients receive two weeks of statin treatment prior to the procedure and one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary outcome of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patient’s perception of health status helps in better recover
7. HIV infected patients can travel safely abroad
8. New vaccine helps allergy and asthma patients
9. Doctors operate upon patients in candlelight- latest from the quake scene
10. New vaccine helps allergy and asthma patients
11. Are cancer patients being taken for a ride?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 30, 2017 , ... This morning, more than 275 medical ... support for an independent Vaccine Safety Commission. Five of the signers of the ... hold a press conference at 9:00 AM Friday, March 31 at the ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has ... of more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers ... and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box ...
(Date:3/29/2017)... New York City, NY (PRWEB) , ... March ... ... governing body for men’s and women’s professional squash, announced it has enlisted New ... marketing partner. The agency will develop and procure sponsorship opportunities for the ...
(Date:3/29/2017)... ... ... main cause of hay fever in the United States, with an estimated 95 percent of ... July each year; with the worst time for sufferers being June and July. , ... provide an effective defense against grass pollen; they are proven in independent studies to trap ...
(Date:3/29/2017)... Amherst, Massachusetts (PRWEB) , ... March 30, 2017 , ... ... has had great success and feedback from high school and college students who have ... is being held July 7-23 and YFI is now accepting applications for enrollment. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  The Global Health Innovative Technology Fund ... to battle infectious diseases around the globe, today ... could help deliver a range of new innovative ... This latest round of targeted support ... testing a pediatric formulation of a drug considered ...
(Date:3/29/2017)... March 29, 2017 Optometrists have staunchly ... the highest standard in quality and care for ... its objective Wavefront-driven refraction technologies and process to ... enables an unprecedented level of refraction and correction ... relegated to Topgun Navy fighter pilots, but now ...
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global lifestyle drugs market to grow at a CAGR of ... Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: